The DOI matches its Crossref record.
Angiotensin II Type 1 Receptor: Relationship With Caveolae and Caveolin After Initial Agonist Stimulation
Abstract
Abstract—Caveolae are membrane domains that have been implicated in signal transduction, and caveolins are major structural components of these domains. We found that all reported caveolin isoforms (caveolin-1, -2, and -3) were expressed in vascular smooth muscle cells (VSMCs); however, only caveolin-1 mRNA was regulated by angiotensin II (Ang II). Ang II (100 nmol/L) increased caveolin-1 mRNA, with a peak at 2 hours (193±6% of control,P<0.01, n=4). In contrast, Ang II significantly decreased caveolin-1 protein, with a nadir at 4 hours (64±5% of control,P<0.01, n=6). [35 S]Methionine labeling showed that Ang II increased caveolin biosynthesis (226±33% of control labeling at 4 hours), suggesting that the transient decrease in caveolin protein levels is due to increased degradation. When cells were fractionated with sucrose, on agonist stimulation, AT 1 receptors appeared in fraction 5 where caveolin was fractionated. This migration was blocked by low temperature and treatment with phenylarsine oxide, interventions that interfere with agonist-induced Ang II type 1 (AT 1) receptor sequestration and tonic phase signaling. In addition, caveolin-1 coimmunoprecipitates with AT 1 receptor only on agonist stimulation. These data support the concept that the caveola is a specialized signaling domain in VSMCs that can be dynamically accessed by the AT 1 receptor. Because of the signaling and coupling proteins that are localized in caveolae and because of evidence that these proteins may interact directly with caveolin, caveola–AT 1 receptor interaction likely represents an important focus for dynamic control of receptor signaling in VSMCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Self-citationLipid rafts: bringing order to chaos
Pike, L. J. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r200021-jlr200 · Cited by 1,138
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,095
Touyz, R. M., & Schiffrin, E. L. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01471-6 · Cited by 934
Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
Brooke, B. S., Habashi, J. P., Judge, D. P., Patel, N., Loeys, B., & Dietz, H. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706585 · Cited by 843
Distinct Subcellular Localizations of Nox1 and Nox4 in Vascular Smooth Muscle Cells
Hilenski, L. L., Clempus, R. E., Quinn, M. T., Lambeth, J. D., & Griendling, K. K. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000112024.13727.2c · Cited by 573
Self-citationHunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
Control of aldosterone secretion: a model for convergence in cellular signaling pathways
SPÄT, A., & HUNYADY, L. (2004) · Physiological Reviews · doi:10.1152/physrev.00030.2003 · Cited by 494
CO AS A CELLULAR SIGNALING MOLECULE
Kim, H. P., Ryter, S. W., & Choi, A. M. K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141053 · Cited by 426
NADPH oxidases and angiotensin II receptor signaling
Garrido, A. M., & Griendling, K. K. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.003 · Cited by 386
Self-citationLocalizing NADPH Oxidase–Derived ROS
Ushio-Fukai, M. (2006) · Science's STKE · doi:10.1126/stke.3492006re8 · Cited by 385
G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there?
Chini, B., & Parenti, M. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0320325 · Cited by 357
Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren
Stanton, A., Jensen, C., Nussberger, J., & O'Brien, E. (2003) · Hypertension · doi:10.1161/01.hyp.0000101688.17370.87 · Cited by 341
Raveh, B., London, N., Zimmerman, L., & Schueler-Furman, O. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018934 · Cited by 319
Savi, P., Zachayus, J.-L., Delesque-Touchard, N., Labouret, C., Hervé, C., Uzabiaga, M.-F., Pereillo, J.-M., Culouscou, J.-M., Bono, F., Ferrara, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510446103 · Cited by 317
Poor uterine contractility in obese women
Zhang, J., Bricker, L., Wray, S., & Quenby, S. (2007) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01233.x · Cited by 316
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Yarbrough, T. L., Lu, T., Lee, H.-C., & Shibata, E. F. (2002) · Circulation Research · doi:10.1161/hh0402.105177 · Cited by 259
Metadata
- Authors
- Ishizaka, N., Griendling, K. K., Lassègue, B., & Alexander, R. W.
- Venue
- Hypertension
- Published
- 1998-09
- Volume
- 32
- Issue
- 3
- Pages
- 459-466
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2116309149
- Cited by
- 225
- References
- 0
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.